SCHEMBL3720893

SCHEMBL3720893

COc1cc(OC(C)C)ccc1O

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAOB P27338 1/20 0.53
CES2 O00748 1/20 0.52
SLC22A6 Q4U2R8 1/20 0.52
SLC22A8 Q8TCC7 1/20 0.52
MEN1 O00255 1/20 0.52
RAB9A P51151 1/20 0.52
KMT2A Q03164 1/20 0.52
FOS P01100 1/20 0.51
TTR P02766 1/20 0.51
JUN P05412 1/20 0.51
NR3C1 P04150 1/20 0.51
HSD17B1 P14061 1/20 0.51
HSD17B2 P37059 1/20 0.51
NFE2L2 Q16236 1/20 0.50
HTT P42858 1/20 0.50
TSHR P16473 3/20 0.49
BLM P54132 1/20 0.49
NPSR1 Q6W5P4 1/20 0.49
ALOX15 P16050 1/20 0.47
ALOX12 P18054 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9647072 0.88 PARP10 (0.50) CES2KMT2AALDH1A1GAA
SCHEMBL20007759 0.85 CA12 (0.52) MAOBMEN1RAB9AKMT2AFOS
SCHEMBL10636549 0.82 CA2 (0.64) MEN1RAB9AKMT2ATSHRNPSR1
SCHEMBL595280 0.81 MAOB (0.64) MAOBSLC22A6SLC22A8MEN1RAB9A
SCHEMBL28497994 0.81 TSHR (0.50) MAOBSLC22A6SLC22A8MEN1RAB9A
SCHEMBL19612492 0.80 CA12 (0.56) MEN1RAB9AKMT2ANPSR1ERN1
SCHEMBL9413246 0.80 SLC22A6 (0.47) MAOBSLC22A6SLC22A8MEN1RAB9A
SCHEMBL1052924 0.79 ALDH1A1 (0.52) KMT2AALDH1A1GAA
SCHEMBL1476982 0.79 MAOB (0.61) MAOBSLC22A6SLC22A8MEN1RAB9A
SCHEMBL377390 0.79 SLC22A6 (0.55) MAOBSLC22A6SLC22A8MEN1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20150191430-A1 CONJUGATES OF HUPERZINE AND ANALOGS THEREOF BISCAYNE NEUROTHERAPEUTICS, INC. 2015-07-09 US disclosed
WO-2010127208-A1 INHIBITORS OF ACETYL-COA CARBOXYLASE FOREST LABORATORIES HOLDINGS LIMITED (BM) 2010-11-04 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150191430-A1 CONJUGATES OF HUPERZINE AND ANALOGS THEREOF HTT, HNMT, GAP43 MAOB 160/4885CES2 178/4885SLC22A6 1079/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.